Veracyte Inc (VCYT) reported better-than-expected financial results for the third quarter of fiscal 2025. The company achieved earnings per share (EPS) of $0.24, exceeding Wall Street's consensus estimate of $0.13 by $0.11. Revenue matched expectations at $0.1 billion.
The results highlight Veracyte's operational strength in the biotechnology sector, where it engages in the research, development, and commercialization of diagnostic products. The company is headquartered in South San Francisco, California, and employs 824 full-time staff. Veracyte's diagnostics platform delivers cancer tests informed by extensive genomic and clinical data, alongside advanced bioinformatics and AI capabilities.
The firm offers tests for various cancers, including prostate (Decipher Prostate), thyroid (Afirma), breast (Prosigna), and bladder (Decipher Bladder). Notably, it has developed the noninvasive Percepta Nasal Swab test to assess lung cancer risk. All tests are conducted in its Clinical Laboratory Improvement Amendments (CLIA) certified laboratories located in South San Francisco, San Diego, and Austin.
Veracyte's market capitalisation stands at $3,295.56 million, with a trailing twelve-month price-to-earnings (P/E) ratio of 125.14. The company is scheduled to host an earnings conference call at the close of trading to discuss these results and provide further insights into its business performance.
Investors are encouraged to review the complete earnings release and listen to management commentary for a comprehensive understanding of the quarter's performance and future outlook. Upcoming earnings are anticipated on 3 August 2026, with an EPS estimate of 0.2448 and revenue projected at $0.1 billion.